These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 11060723)
21. Ribozymes as anti-HIV-1 therapeutic agents: principles, applications, and problems. Rossi JJ; Elkins D; Zaia JA; Sullivan S AIDS Res Hum Retroviruses; 1992 Feb; 8(2):183-9. PubMed ID: 1540406 [TBL] [Abstract][Full Text] [Related]
22. Structural similarities between hammerhead ribozymes and the spliceosomal RNAs could be responsible for lack of ribozyme cleavage in yeast. Castanotto D; Li H; Chow W; Rossi JJ; Deshler JO Antisense Nucleic Acid Drug Dev; 1998 Feb; 8(1):1-13. PubMed ID: 9512091 [TBL] [Abstract][Full Text] [Related]
23. Efficacy and mode of action of hammerhead and hairpin ribozymes against various HIV-1 target sites. Hotchkiss G; Maijgren-Steffensson C; Ahrlund-Richter L Mol Ther; 2004 Jul; 10(1):172-80. PubMed ID: 15233952 [TBL] [Abstract][Full Text] [Related]
24. Multitarget-ribozyme directed to cleave at up to nine highly conserved HIV-1 env RNA regions inhibits HIV-1 replication--potential effectiveness against most presently sequenced HIV-1 isolates. Chen CJ; Banerjea AC; Harmison GG; Haglund K; Schubert M Nucleic Acids Res; 1992 Sep; 20(17):4581-9. PubMed ID: 1408760 [TBL] [Abstract][Full Text] [Related]
25. Hammerhead ribozymes as therapeutic agents for bladder cancer. Irie A; Kashani-Sabet M; Scanlon KJ; Uchida T; Baba S Mol Urol; 2000; 4(2):61-6. PubMed ID: 12006244 [TBL] [Abstract][Full Text] [Related]
27. Ribozymes: a modern tool in medicine. Khan AU; Lal SK J Biomed Sci; 2003; 10(5):457-67. PubMed ID: 12928586 [TBL] [Abstract][Full Text] [Related]
28. [Reversal of drug resistance in human cancer cells by anti-oncogenes]. Funato T Gan To Kagaku Ryoho; 1997 Feb; 24(4):395-400. PubMed ID: 9063474 [TBL] [Abstract][Full Text] [Related]
29. A multifunctional expression vector for an anti-HIV-1 ribozyme that produces a 5'- and 3'-trimmed trans-acting ribozyme, targeted against HIV-1 RNA, and cis-acting ribozymes that are designed to bind to and thereby sequester trans-activator proteins such as Tat and Rev. Yuyama N; Ohkawa J; Koguma T; Shirai M; Taira K Nucleic Acids Res; 1994 Nov; 22(23):5060-7. PubMed ID: 7800500 [TBL] [Abstract][Full Text] [Related]
30. The potential use of catalytic RNAs in therapy of HIV infection and other diseases. Rossi JJ; Cantin EM; Sarver N; Chang PF Pharmacol Ther; 1991; 50(2):245-54. PubMed ID: 1763136 [TBL] [Abstract][Full Text] [Related]
35. Application of preformed hammerhead ribozymes in the gene therapy of cancer (review). Sioud M Int J Mol Med; 1999 Apr; 3(4):381-4. PubMed ID: 10085409 [TBL] [Abstract][Full Text] [Related]
36. Ribozymes: applications to functional analysis and gene discovery. Shiota M; Sano M; Miyagishi M; Taira K J Biochem; 2004 Aug; 136(2):133-47. PubMed ID: 15496583 [TBL] [Abstract][Full Text] [Related]
37. A cis and trans adenine-dependent hairpin ribozyme against Tpl-2 target. Li YL; Torchet C; Vergne J; Maurel MC Biochimie; 2007 Oct; 89(10):1257-63. PubMed ID: 17703868 [TBL] [Abstract][Full Text] [Related]
38. Ribozymes: the characteristics and properties of catalytic RNAs. Tanner NK FEMS Microbiol Rev; 1999 Jun; 23(3):257-75. PubMed ID: 10371033 [TBL] [Abstract][Full Text] [Related]
39. Ribozymes, DNAzymes and small interfering RNAs as therapeutics. Sioud M; Iversen PO Curr Drug Targets; 2005 Sep; 6(6):647-53. PubMed ID: 16178798 [TBL] [Abstract][Full Text] [Related]
40. Designing of chimeric DNA/RNA hammerhead ribozymes to be targeted against AML1/MTG8 mRNA. Kozu T; Sueoka E; Okabe S; Sueoka N; Komori A; Fujiki H J Cancer Res Clin Oncol; 1996; 122(4):254-6. PubMed ID: 8601580 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]